|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||13.25 - 13.25|
|52-week range||13.25 - 13.25|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Clinigen Group plc ( LON:CLIN ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...
BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...